Chengdu Chipscreen Pharmaceutical Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Sunshine Lake Pharma Co. Ltd. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated the role of DHX9 in cancer using the tool compound ATX-968, designed as a potent and selective small-molecule inhibitor of DHX9.
Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 signaling specifically in the context of PD-L1 while simultaneously blocking PD-1/PD-L1 signaling.
Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe form. There is an urgent need to unravel the molecular mechanisms behind PAH and identify new targets, especially those involved in the remodeling process. The proliferation and resistance to apoptosis of pulmonary artery smooth muscle cells are key contributors to pulmonary vascular remodeling in PAH.
Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are shared, nonmutated, aberrantly expressed antigens that are derived from what were thought to be noncoding regions of the genome.
Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors targeting STAT6 may help prevent and treat allergic diseases, asthma, atopic dermatitis or other Th2-driven immune conditions. Researchers from Recludix Pharma Inc. have presented the preclinical profiles of REX-8756 and REX-4671, two STAT6 inhibitors being developed in partnership with Sanofi SA.
RSS
